ARVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Arvinas Inc (ARVN) is not a strong buy for a beginner, long-term investor at this time. Despite recent analyst upgrades and potential upside, the company's financial performance is deteriorating, insider selling is significant, and technical indicators do not show a clear bullish trend. The lack of strong proprietary trading signals further supports a cautious approach.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 50.148, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key support is at $11.583, and resistance is at $13.646.
Analyst upgrades from Citi and Barclays with increased price targets ($15 and $18, respectively) signal optimism for the stock's future. The biotech sector's 2026 outlook could provide opportunities for ARVN.
Significant insider selling (up 10786.55% over the last month) raises concerns about internal confidence. The recent CEO change led to an 11% drop in stock price due to market concerns. Financials show declining revenue (-59.08% YoY) and net income (-28.66% YoY).
In Q3 2025, revenue dropped by 59.08% YoY to $41.9M, net income fell by 28.66% YoY to -$35.1M, and EPS decreased by 29.41% YoY to -$0.48. Gross margin remained flat at 100%.
Recent upgrades from Citi (Buy, $15 PT) and Barclays (Overweight, $18 PT) show optimism. However, the stock's financial struggles and insider selling may limit immediate upside.
